Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.

BIO·NYSE

$304.83

+0.14%
HealthcareMedical - Devices

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

At a Glance

Live Snapshot
Market Cap$8.24B
EPS27.8700
P/E Ratio10.94
Earnings Date07/30/2026
2.04%
Return on Invested Capital
-14%
3Y-29.0%
5Y-23.0%
10Y+92.0%
10.20%
Return on Equity
-136%
3Y-127.0%
5Y-74.0%
10Y+835.0%
7.18%
Return on Assets
-136%
3Y-127.0%
5Y-76.0%
10Y+884.0%
Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. Management Team

BIO · NYSE
MN

Mr. Norman D. Schwartz

Chairman & Chief Executive Officer

Compensation

$1,451,580

Born 1950(Age 76)
male
MR

Mr. Roop K. Lakkaraju CPA

Executive Vice President & Chief Financial Officer

Compensation

$692,222

Born 1971(Age 55)
male
MA

Ms. Anette Engelhardt

Executive Vice President & President of the Clinical Diagnostics Group

Compensation

$401,446

female
MM

Mr. Michael Crowley

Executive Vice President of Global Commercial Operations

Compensation

$649,798

Born 1962(Age 64)
male
MC

Ms. Colleen Corey

Executive Vice President of Global Human Resources

Born 1962(Age 64)
female
CC

Courtney C. Enloe

Executive Vice President, General Counsel & Secretary

MJ

Mr. Jonathan P. DiVincenzo

President & Chief Operating Officer

Compensation

$1,860,703

Born 1966(Age 60)
male
MW

Matthew Werner

Senior Vice President and Chief Compliance & Privacy Officer

LB

Lee Boyd

Senior Vice President of Global Commercial Operations - Asia Pacific

MY

Mr. Yong Chung

Vice President of Investor Relations

male
bio

Bio-Rad Laboratories, Inc. Insider Positioning

BIO · NYSE

During the last 12 months, insiders have sold $350K worth of BIO shares, with no buying activity reported.

3 Months

Bought

0

0.00

Sold

550

135.60K

Net Activity

-136K

-$136K

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

699

214.02K

Net Activity

-214K

-$214K

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

No buying activity

Top Sellers

1
BJ

Barry James

Officer: Evp, President, Lsg

699 shares1 transactions

$214K

2
EEA

Engelhardt Eva Anette

Officer: Evp, President, Cdg

550 shares1 transactions

$136K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $350K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Recent Trend (3 Months)

$136K

Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.

Insider Participation

High Selling

2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.

Insider Activity Insight

Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.

SEC Filings

BIO - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2026

N/A

March 25, 2026
April 21, 2026
2026
DEF 14A

DEF 14A 2025

N/A

March 26, 2025
April 22, 2025
2025
DEF 14A

DEF 14A 2024

N/A

March 27, 2024
April 23, 2024
2024
DEF 14A

DEF 14A

N/A

March 29, 2023
March 29, 2023
 
DEF 14A

DEF 14A 2022

N/A

March 30, 2022
April 26, 2022
2022
DEF 14A

DEF 14A 2021

N/A

March 31, 2021
April 27, 2021
2021
DEF 14A

DEF 14A 2020

N/A

April 01, 2020
April 28, 2020
2020
DEF 14A

DEF 14A 2019

N/A

April 04, 2019
April 29, 2019
2019
DEF 14A

DEF 14A 2018

N/A

May 04, 2018
May 04, 2018
2018
DEF 14A

DEF 14A 2017

N/A

March 30, 2017
March 30, 2017
2017
Showing 1 to 10 of 32 filings